Neurocrine Biosciences, Inc. – NASDAQ:NBIX

Neurocrine Biosciences stock price today

$132.81
-6.62
-4.75%
Financial Health
0
1
2
3
4
5
6
7
8
9

Neurocrine Biosciences stock price monthly change

-5.42%
month

Neurocrine Biosciences stock price quarterly change

-5.42%
quarter

Neurocrine Biosciences stock price yearly change

+5.03%
year

Neurocrine Biosciences key metrics

Market Cap
13.55B
Enterprise value
N/A
P/E
64.51
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
6.67
Price/Book
5.82
PEG ratio
0.90
EPS
3.76
Revenue
1.98B
EBITDA
482.3M
Income
369.7M
Revenue Q/Q
22.57%
Revenue Y/Y
23.99%
Profit margin
10.38%
Oper. margin
16.73%
Gross margin
98.44%
EBIT margin
16.73%
EBITDA margin
24.33%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Neurocrine Biosciences stock price history

Neurocrine Biosciences stock forecast

Neurocrine Biosciences financial statements

Average Price Target
Last Year

$150.14

Potential upside: 13.05%

Based on estimate of 6 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Profit margin
Jun 2023 452.7M 95.5M 21.1%
Sep 2023 498.8M 83.1M 16.66%
Dec 2023 515.2M 147.7M 28.67%
Mar 2024 515.29M 43.4M 8.42%
Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Debt to assets
Jun 2023 2613100000 760.1M 29.09%
Sep 2023 2848200000 846.1M 29.71%
Dec 2023 3251400000 1.01B 31.35%
Mar 2024 3472400000 1.08B 31.28%
Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Cash Flow
Jun 2023 179.6M -125.9M 2.9M
Sep 2023 212M -97.3M 18.8M
Dec 2023 123.5M -201.8M 35.4M
Mar 2024 130.3M -55M 69.9M

Neurocrine Biosciences alternative data

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Employee count
Aug 2023 1,300
Sep 2023 1,350
Oct 2023 1,350
Nov 2023 1,350
Dec 2023 1,400
Jan 2024 1,400
Feb 2024 1,400
Mar 2024 1,400
Apr 2024 1,400
May 2024 1,400
Jun 2024 1,448
Jul 2024 1,448

Neurocrine Biosciences other data

90.73% -0.39%
of NBIX is owned by hedge funds
88.55M -649.16K
shares is hold by hedge funds

Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 277731
Feb 2024 0 74279
Mar 2024 0 144521
Apr 2024 0 12859
May 2024 0 87358
Jul 2024 0 22863
Aug 2024 0 62964
Sep 2024 0 3461
Oct 2024 0 1295
Nov 2024 0 2331
Dec 2024 0 1091
Transaction Date Insider Security Shares Price per share Total value Source
Option
DELAET INGRID officer: Chief Regulatory Officer
Non-Qualified Stock Option 1,091 $79.02 $86,211
Sale
DELAET INGRID officer: Chief Regulatory Officer
Common Stock 1,091 $135 $147,285
Option
DELAET INGRID officer: Chief Regulatory Officer
Common Stock 1,091 $79.02 $86,211
Option
ONYIA JUDE officer: Chief Scientific Officer
Common Stock 4,426 N/A N/A
Sale
ONYIA JUDE officer: Chief Scientific Officer
Common Stock 2,331 $126.29 $294,373
Option
ONYIA JUDE officer: Chief Scientific Officer
Restricted Stock Unit 4,426 N/A N/A
Option
ROBERTS EIRY officer: Chief Me.. Common Stock 1 $79.02 $79
Option
ROBERTS EIRY officer: Chief Me.. Common Stock 971 $102.9 $99,916
Option
ROBERTS EIRY officer: Chief Me.. Common Stock 1,233 $81.05 $99,935
Option
ROBERTS EIRY officer: Chief Me.. Common Stock 5,140 $77.81 $399,943
Friday, 20 December 2024
https://thefly.com
prnewswire.com
Wednesday, 18 December 2024
seekingalpha.com
Friday, 13 December 2024
investors.com
prnewswire.com
reuters.com
Tuesday, 26 November 2024
prnewswire.com
Friday, 8 November 2024
seekingalpha.com
Thursday, 7 November 2024
prnewswire.com
Tuesday, 5 November 2024
prnewswire.com
Monday, 4 November 2024
prnewswire.com
prnewswire.com
Wednesday, 30 October 2024
seekingalpha.com
zacks.com
zacks.com
prnewswire.com
Wednesday, 23 October 2024
zacks.com
Thursday, 10 October 2024
seekingalpha.com
Wednesday, 9 October 2024
prnewswire.com
Monday, 30 September 2024
prnewswire.com
Thursday, 19 September 2024
prnewswire.com
Thursday, 12 September 2024
reuters.com
prnewswire.com
Tuesday, 10 September 2024
prnewswire.com
Friday, 30 August 2024
fool.com
Thursday, 29 August 2024
benzinga.com
zacks.com
Wednesday, 28 August 2024
seekingalpha.com
prnewswire.com
seekingalpha.com
  • What's the price of Neurocrine Biosciences stock today?

    One share of Neurocrine Biosciences stock can currently be purchased for approximately $132.81.

  • When is Neurocrine Biosciences's next earnings date?

    Unfortunately, Neurocrine Biosciences's (NBIX) next earnings date is currently unknown.

  • Does Neurocrine Biosciences pay dividends?

    No, Neurocrine Biosciences does not pay dividends.

  • How much money does Neurocrine Biosciences make?

    Neurocrine Biosciences has a market capitalization of 13.55B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.76% to 1.89B US dollars.

  • What is Neurocrine Biosciences's stock symbol?

    Neurocrine Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "NBIX".

  • What is Neurocrine Biosciences's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Neurocrine Biosciences?

    Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Neurocrine Biosciences's key executives?

    Neurocrine Biosciences's management team includes the following people:

    • Dr. Kevin C. Gorman Ph.D. Chief Executive Officer & Director(age: 67, pay: $1,380,000)
    • Dr. Eiry Wyn Roberts Chief Medical Officer(age: 61, pay: $847,940)
    • Mr. Matthew C. Abernethy Chief Financial Officer(age: 45, pay: $781,040)
    • Mr. Eric S. Benevich Chief Commercial Officer(age: 60, pay: $748,830)
    • Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer(age: 52, pay: $711,720)
  • How many employees does Neurocrine Biosciences have?

    As Jul 2024, Neurocrine Biosciences employs 1,448 workers, which is 3% more then previous quarter.

  • When Neurocrine Biosciences went public?

    Neurocrine Biosciences, Inc. is publicly traded company for more then 29 years since IPO on 23 May 1996.

  • What is Neurocrine Biosciences's official website?

    The official website for Neurocrine Biosciences is neurocrine.com.

  • Where are Neurocrine Biosciences's headquarters?

    Neurocrine Biosciences is headquartered at 12780 El Camino Real, San Diego, CA.

  • How can i contact Neurocrine Biosciences?

    Neurocrine Biosciences's mailing address is 12780 El Camino Real, San Diego, CA and company can be reached via phone at 858 617 7600.

  • What is Neurocrine Biosciences stock forecast & price target?

    Based on 6 Wall Street analysts` predicted price targets for Neurocrine Biosciences in the last 12 months, the avarage price target is $150.14. The average price target represents a 13.05% change from the last price of $132.81.

Neurocrine Biosciences company profile:

Neurocrine Biosciences, Inc.

neurocrine.com
Exchange:

NASDAQ

Full time employees:

1,700

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

12780 El Camino Real
San Diego, CA 92130

CIK: 0000914475
ISIN: US64125C1099
CUSIP: 64125C109